CURRENT REPORT 32/2021
November 4, 2021

Clinical and Translational Data from RVU120 and SEL24(MEN1703) programs to be presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition and the 44th Annual San Antonio Breast Cancer Symposium (SABCS)

The Management Board of Ryvu Therapeutics S.A. ("Company", "Ryvu") hereby announces that five abstracts demonstrating clinical and preclinical activity of selective CDK8/19 inhibitor RVU120 (SEL120) and selective PIM/FLT3 inhibitor SEL24 (MEN1703) have been accepted for presentation at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition, to be held on December 11 – December 14, 2021 in Atlanta (USA). A poster on the preclinical efficacy of RVU120 in breast cancer has also been accepted for presentation at the 44th Annual San Antonio Breast Cancer Symposium (SABCS) to be held on December 7 – December 10, 2021, in San Antonio (USA). Ryvu’s partner Menarini Group will be presenting SEL24/MEN1703 data from the First-in-Human, Dose Escalation (DE) and Cohort Expansion (CE) CLI24-001 trial (DIAMOND-01, ClinicalTrials.gov identifier: NCT03008187).

RVU120 has demonstrated an acceptable safety profile and early signs of efficacy in patients harboring DNMT3A mutations, including a Complete Response, in the first five dose cohorts. Preclinical models show potential for clinical efficacy of RVU120 in breast cancer.

During the conference ASH Annual Meeting & Exposition the Company will present the following abstracts:

**CLI120-001 Phase Ib Study of RVU120(SEL120) in Patients with AML and High Risk MDS: Updated Safety/Efficacy Results from Initial Dose Escalation** (Publication Number: 3418), Camille Abboud Sr., MD (Washington University in Saint Louis/ Washington University School of Medicine) et al.

- Session Name: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster III
- Date: Monday, December 13, 2021
- Presentation Time: 6:00 PM - 8:00 PM

**RVU120 (SEL120) CDK8/19 Inhibitor - a Drug Candidate for the Treatment of MDS Can Induce Erythroid Differentiation** (Publication Number: 1518), Tomasz Rzymski, PhD (Ryvu Therapeutics) et al.

- Session Name: 636. Myelodysplastic Syndromes—Basic and Translational: Poster I
- Date: Saturday, December 11, 2021
- Presentation Time: 5:30 PM - 7:30 PM
Inhibition of Cyclin Dependent Kinase 8 (CDK8): A Novel Approach to Target the Leukemia Initiating Cells (LICs) in T-Cell Acute Lymphoblastic Leukaemia (T-ALL) (Publication Number: 2250), Sujan Piya, PhD (MD Anderson Cancer Center) et al.

- Session Name: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II
- Date: Sunday, December 12, 2021
- Presentation Time: 6:00 PM - 8:00 PM

Preclinical and Clinical Signs of Efficacy of RVU120 (SEL120), a Specific CDK8/19 Inhibitor in DNMT3A-Mutated AML (Publication Number: 2371), Tomasz Rzymski, PhD (Ryvu Therapeutics) et al.

- Session Name: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II
- Date: Sunday, December 12, 2021
- Presentation Time: 6:00 PM - 8:00 PM

SEL24(MEN1703) Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial (Publication Number: 3436), Alessandro Paoli (Menarini Group) et al.

- Session Name: 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III
- Date: Monday, December 13, 2021
- Presentation Time: 6:00 PM - 8:00 PM

The abstract accepted for the poster presentation at the 2021 San Antonio Breast Cancer Symposium®, taking place on December 7-10, 2021, at Henry B. Gonzalez Convention Centre in San Antonio, Texas:

Selective CDK8/CDK19 inhibitor RVU120 demonstrates efficacy against hormone-independent breast cancer cells in vitro and in vivo (#1766), Tomasz Rzymski, PhD (Ryvu Therapeutics) et al.

- Program Number: P5-17-13
- Poster Session 5: December 10, 2021: 7:00 AM – 8:30 AM

During the poster presentations an acceptable safety profile and early signs of efficacy will be presented for RVU120, a selective CDK8/19 inhibitor being developed in hematologic and solid tumors, in the first-in-human (FIH) Phase Ib dose escalation trial (CLI120-001) currently ongoing in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-
MDS). The preliminary signs of efficacy for RVU120 include a complete response (CR) in AML and an erythroid response (ER) in HR-MDS patients, relapsed after several lines of previous treatment.

Translational research will be presented that potentially links the clinical response in an AML patient to DNMT3A-mutations via evidence in DNMT3A-mutated AML patient-derived cells (PDCs). Further translational research shows evidence that the clinical erythroid response in an MDS patient is potentially a result of strong erythroid differentiation potential of RVU120 in preclinical models. Enrollment is ongoing in cohort 4 at seven locations in the US and Europe to gather additional safety data in the study.

Both the ASH conference and the San Antonio Breast Cancer Symposium are considered to be one of the most important scientific events, gathering researchers, as well as potential clients and business partners - biotechnology and pharmaceutical companies from all over the world and industry investors.

Legal basis: art. 17 ust. 1 MAR

Representatives of the Company:

- Paweł Przewięźlikowski – President of the Management Board, CEO
- Krzysztof Brzózka – Vice President of the Management Board, CSO